Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood and tissue test could spot High-Risk lung cancer patients early

NCT ID NCT05557474

Diagnosis Sponsor: Chung Shan Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing two new diagnostic kits that use blood samples or tumor tissue to predict if early-stage lung cancer will come back after surgery. Researchers will enroll 236 people with stage IA to IIIA lung cancer who have had their tumor fully removed. The goal is to see if these kits can accurately identify patients at higher risk of recurrence, which could help doctors decide on additional treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ELISA and IHC diagnostic kits
What this could lead to
If successful, this could help doctors identify which early-stage lung cancer patients are at high risk of recurrence, enabling more tailored follow-up and treatment.
What could go wrong
This is a relatively small, single-center study focused on diagnostic accuracy, not a treatment. The kits may not prove reliable enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 236 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Early stage lung adenocarcinoma post-surgical follow up

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing to sign and provide subject consent. * Male or female of age 20 or older. * Patients diagnosed with lung adenocarcinoma by tumor pathology. * Lung cancer with the pathological stage of IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition). * Complete tumor resection (R0 resection). * The East Coast Cancer Clinical Research Collaborative (ECOG) performance status was 0 or 1 at the time of grouping. * Those willing to provide tumor tissue or cytology specimens (including surgical specimens, tissue biopsy specimens, or cytology specimens), blood and body fluid specimens (for follow-up or disease recurrence, such as urine, malignant pleural effusion, ascites, pericardial fluid, etc.). Exclusion Criteria: * Not primary lung cancer patients. * Lung cancer patients whose pathological stage is not IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition) after surgery. * Patients with uncontrolled malignant tumors other than lung cancer. * Uncontrolled systemic disease (such as diabetes, hypertension, active infection, etc.) (determined by the principal investigator ) * Pregnant women. * Any condition may put the patient at serious risk, may affect the interpretation of the trial results, or may seriously interfere with the patient's participation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma lung cancer lung neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer Recurrence Surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chung Shan Medical University Hospital

    RECRUITING

    Taichung, Taiwan, 402, Taiwan

  • National Taiwan University, Cancer Center

    RECRUITING

    Taipei, 106, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.